Clinical Trials Browser

Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

766 enrolled

Breast

Breast Neoplasms

NCT02344940 2019-09-24

TTOS

Phase 4 Completed

104 enrolled

Breast

Breast Neoplasms

NCT02506790 2019-09-04

Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer

Phase 2 Unknown

96 enrolled

Breast

Breast Neoplasms

NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Phase 4 Withdrawn

Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT03351062 2017-11-22

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Phase 3 Unknown

844 enrolled

Breast

Breast Neoplasms

NCT02097459 2016-05-25

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

Phase 3 Unknown

600 enrolled

Breast

Breast Neoplasms

NCT00044291 2015-07-31

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3 Completed

865 enrolled

Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT02132390 2014-06-04

Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

Phase 3 Unknown

300 enrolled

Breast

Breast Neoplasms

NCT00010322 2014-03-26

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 3 Terminated

Breast

Breast Neoplasms

NCT00002529 2013-04-04

12-93

Phase 3 Completed

452 enrolled

Breast

Breast Neoplasms

NCT00437359 2012-03-30

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

Phase 2 Terminated

240 enrolled

Breast

Breast Neoplasms

NCT00267553 2007-09-10

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Phase 3 Terminated

200 enrolled

Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3 Terminated

842 enrolled

Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Clinical Trials

CAMERAN

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

TTOS

Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

12-93

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer